Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
Shionogi reported record-high sales and operating profit for the fourth consecutive year in FY2025 ended March 2026, driven by the acquisition of Torii Pharmaceutical and continued growth of its in-house products in Japan and overseas. According to its consolidated earnings…
To read the full story
Related Article
- Shionogi to Absorb Torii in April 2027
February 24, 2026
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
- Shionogi Completes Takeover of JT’s Pharma Business
December 2, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Shionogi, Torii to Start Co-Promotion in September upon Takeover
July 29, 2025
- Shionogi Clinches Tender Offer for Torii, Sets Stage for Full Takeover by September
June 20, 2025
- Shionogi Nets Record Earnings for 3rd Consecutive Year on Overseas Expansion
May 13, 2025
- Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
- Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
October 29, 2024
- Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
May 11, 2023
- Shionogi Hits Record High Earnings on Xocova Boon in FY2022
May 11, 2023
- Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
- Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
November 1, 2022
- Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
- Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
August 2, 2022
- Shionogi’s Sales Rise 12.8% in FY2021 on Cefiderocol Growth in US/Europe
May 12, 2022
- Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
- Shionogi Ups FY2021 Earnings Outlook on HIV Patent Suit Settlement
April 26, 2022
- Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D
February 1, 2022
- Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear
November 2, 2021
- Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
August 3, 2021
- Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
May 11, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
August 3, 2020
BUSINESS
- Japan Pharma Market Grows 3.8% in FY2025 as Protected Brands Shine: IQVIA
July 13, 2026
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…